New Clinical Data Highlights Caplyta® (Lumateperone) As A Promising Option For Achieving Remission In Adults With Major Depressive Disorder
Jan 16 (Reuters) - Johnson & Johnson JNJ.N:
NEW CLINICAL DATA HIGHLIGHTS CAPLYTA® (LUMATEPERONE) AS A PROMISING OPTION FOR ACHIEVING REMISSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER
J&J - 65% REACHED REMISSION WITH CAPLYTA, 43% SUSTAINED RELIEF IN SIX MONTHS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.